Physician profile
Robert Stephenson
NPI 1386642478
$9,760.26
in general payments reported to CMS, 2019-2025
50 companies · $1,218 in 2025
The $1,218 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $645 · 2020: $1,234 · 2021: $1,895 · 2022: $1,745 · 2023: $1,783 · 2024: $1,242 · 2025: $1,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,240 · Travel and Lodging: $2.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,239.74 |
| Travel and Lodging | $2.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,039.60 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $1,293.66 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,264.09 | 2020-2025 | Ubrelvy, Vraylar, Qulipta |
| Pfizer INC. | $800.81 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $554.51 | 2019-2024 | Xifaxan |
| Lilly USA, LLC | $543.05 | 2020-2025 | Kisunla, Mounjaro, Jardiance |
| Novo Nordisk INC | $521.87 | 2020-2025 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $346.46 | 2022-2023 | |
| Allergan, INC. | $239.74 | 2020 | |
| Amgen INC. | $217.75 | 2022-2025 | Evenity, Prolia, Prolia |
| Novartis Pharmaceuticals Corporation | $191.19 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.61 | 2019-2024 | |
| Eisai INC. | $150.56 | 2021-2022 | |
| Abbott Laboratories | $132.33 | 2021-2024 | Freestyle Libre 3 |
| Seqirus USA INC | $124.89 | 2022-2025 | Flucelvax, Fluad, Flucelvax Quadrivalent |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Stephenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.